Stocks
Citigroup Boosts Amgen Price Target to $405
Citigroup has made an adjustment to its price target for Amgen (AMGN), raising it from $345 to $405 while maintaining a neutral rating. This change reflects the bank's ongoing assessment of the biotech company's performance and prospects.
The move comes as Citigroup continues to monitor the market and make adjustments to its forecasts based on changing conditions and new information. As a leading technology company, Amgen has been a focus of interest for analysts and investors alike due to its innovative products and significant impact on the broader economy.